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Abstract
Background: Photoelectrochemical oxidation (PECO) is a new air purification technology developed to reduce circulating
indoor allergens. PECO removes particles as small as 0.1 nm with the destruction of organic matter otherwise not trapped
by a traditional filter and removes volatile organic compounds.
Objective: We hypothesized that with daily use, the device would reduce user nasal and ocular allergy total symptom
scores (TSS) within 4 weeks.
Methods: The study was performed among 46 individuals with self-reported allergies using a portable PECO air purifier.
Self-reported TSS were calculated at baseline and weekly for 4 weeks following initiation of continuous use of the system.
TSS was the sum of total nasal symptom scores (TNSS) and total ocular symptom scores (TOSS) for the week.
Results: There was a statistically significant change in overall TSS from baseline to 4 weeks (10.1 at baseline and 4.35
postintervention) resulting in a mean difference of 5.75 (95% confidence interval [CI] 4.32–7.18; P <.0001). There was
a statistically significant change in TNSS from baseline to 4 weeks (6.3 at baseline and 3.04 postintervention) resulting in a
mean difference of 3.26 (95% CI 2.33–3.19; P <.0001). There was a statistically significant change in TOSS from baseline to
4 weeks (3.82 at baseline and 1.3 postintervention) resulting in a mean difference of 2.52 (95% CI 1.74–3.3; P <.0001).
Conclusion: With the use of PECO air purification technology, TSS, TNSS, and TOSS decreased significantly. These
improvements were consistent over the 4-week course of device use.
Keywords
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Introduction
In the United States, the incidence of respiratory allergies and asthma is increasing, with 10% to 40% of the
population suffering from allergies1 and 8% suffering
from asthma.2 The direct and indirect health costs and
decrement in quality of life from these illnesses are substantial.2,3 While these symptoms are typically attributed
to aeroallergens, there are particulate matter and volatile
organic compounds (VOCs) that act as irritants that can
also evoke symptoms. Local air filtration has shown
some ability to decrease allergen counts in the air and
thus improve the symptoms experienced by allergy and
asthma sufferers under certain conditions4. However, to
date, the efficacy of a comprehensive air purification
system, particularly with high-efficiency particulate air

(HEPA) filtration, as a sole intervention modality has
been equivocal and the extent of air filtration
remains suboptimal.
Photoelectrochemical oxidation (PECO) is a revolutionary new technology for providing an air purification
solution. In addition to physical filtration, a
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photoelectrochemical reaction takes place on the surface
of a nano-coated filter leading to the oxidation of organic matter. These processes allow for the destruction of
organic material 1000 times smaller than what a HEPA
filter can capture.5,6 Thus, PECO not only removes but
can also efficiently destroy organic matter, bacteria,
viruses, mold, and VOCs converting them into their
trace elements.7
In this report, we present the results of our initial
experience using portable PECO air purification technology in the home with users who complained of respiratory allergy symptoms and some of whom also suffered
from asthma.

Description of PECO Technology
(molekule.com)
PECO is a catalytic oxidation reaction in which photons
of light that have energy more than the bandgap of a
photocatalyst excite the photocatalyst which produces
hydroxyl free radicals in the presence of water molecules
in air. The hydroxyl free radicals are extremely potent
oxidizers, which oxidize organics and microorganisms in
air to form CO2 and water and trace minerals. Equations
(1) to (5) describe the chemical reactions.

Photocatalyst þ PhotonðhÞ ! holeþ
vb þ e

(1)

H2 O ! OH þ Hþ

(2)


•
holeþ
vb þ OHads ! OH

(3)

2Hþ 2e þ

1
O2 ! H 2 O
2

(4)

Oxidation of organics
OH• þ Organics þ O2 ! ProductsðCO2 ; H2 O; etc:Þ
(5)
The pioneering work in the field of photocatalytic
disinfection of indoor air was done by Goswami et al.
when they developed a technology to completely destroy
biological contaminants in indoor air.8,9 Wolfrum et al.
demonstrated complete mineralization of Escherichia
coli, Micrococcus luteus, Bacillus cereus (bacterial cells
and spores), and Aspergillus niger spores by photocatalytic oxidation.10 They based their results on kinetic data
and carbon mass balance. Goswami later enhanced the
process by separating the electrons and holes by photoelectrochemical process that improved the effectiveness
of photocatalytic oxidation by orders of magnitude,
which is the underlying technology of Molekule device.

Goswami and his coworkers published a total of 18 peerreviewed papers in scientific journals. In a final paper,
Goswami and his group explained the whole disinfection
process by PECO.11

Methods
We performed a prospective cohort study evaluating the
use of a portable air purifier with PECO technology
from March 2015 to April 2017. The study was approved
by the institutional review board at IntegReview, Austin,
TX and written consent was obtained. Consecutive adult
subjects older than 18 volunteered to test the unit for a
1-month trial period. Volunteers were not paid and were
identified through social media outreach. All subjects
expressed interest in testing the new air purification technology to see if it helped their allergies and/or asthma.
All subjects had some degree of nasal or ocular allergy symptoms and some also suffered from asthma symptoms. Some participants primarily agreed to test the unit
to see if it helped with their sleep or overall quality life.
Instructions were given that participants should use the
air purifier for a minimum of 12 h/day and preferably at
nighttime with the unit close to the bed if possible.
During the study duration, participants were advised
to continue their normal medications for allergic symptoms, asthma, and any other general medical condition
and to continue their usual routine for managing allergies and asthma. The duration of the study was 4 weeks.
Symptoms were self-recorded weekly.

Outcome Measures
The primary outcome for the study was change in overall symptom scores from baseline to the scores at 4
weeks. The secondary outcomes were change in overall
symptom score, total nasal symptom scores (TNSS),
total ocular symptom scores (TOSS), and sleep quality
from baseline to the 1- and 4-week time points, and
change in asthma symptoms from baseline to the
4-week time point. Data on all outcomes were collected
at baseline and weekly over 4 weeks via a web-based
survey tool. The TNSS and TOSS tool is a validated
tool and has been widely used. Briefly, TNSS consist
of patient rating of the degree of nasal congestion,
runny nose, nasal itchiness, and sneezing, while TOSS
consist of patient rating of the degree of eye itchiness,
eye wateriness, and eye redness.12,13 Both are graded on
a scale of 0 to 3 where 0 represented no symptoms, 1—
mild symptoms, 2—moderate symptoms, and 3—severe
symptoms. Total symptom scores (TSS) are the sum of
TNSS and TOSS. Participants with at least some moderate nasal or ocular symptoms and TSS of 8 or greater
at baseline were considered to have active respiratory
allergies (allergy subjects). Sleep quality was assessed
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on a scale of 0 to 3. In the past 4 weeks, please rate how
difficult sleep has been with nasal symptoms on a scale
from 0 to 3 (0—none, 1—mild, 2—moderate, and 3—
severe). Asthma symptoms were recorded on a 0- (minimum) to 4- (maximum) point scale at baseline and at 4
weeks. A point was given for poor control for each question over the past 4 weeks. Questions assessed missed
work or daily activities due to asthma, waking up,
whether asthma was felt to be well controlled, and greater than 12 puffs inhaler use per day.14
Self-reported medication use for allergies and asthma,
dose, frequency, and route were assessed at baseline and
at 4 weeks.

Statistical Analysis
Descriptive statistics (eg, frequency and relative percentages, means, and standard deviations [SDs]) were used
to describe demographic characteristics of included subjects. The change in outcomes following intervention
was compared using paired t tests and summarized as
mean differences along with 95% confidence intervals
(CIs). For the ease of interpretation, summary measures
from continuous data were converted into odds ratio
along with 95% CI.15 The statistical significance was
set at P < .05 for all comparisons. All analyses were performed using SPSS statistical analysis software version 23.

Results
Participant Characteristics
A total of 49 adult patients volunteered to participate in
using the portable air purifier. Forty-seven percent of the
participants were male (n ¼ 23) and 53% were females
(n ¼ 26) (Table 1). The mean age of the participants was
39.8 years (SD  12.6; range 18–77 years). The majority
of the participants (73%; n ¼ 36) had active allergies
with baseline TSS greater than or equal to 8. Some of
the participants had, in addition to allergies, a history of
asthma (36%; n ¼ 18).

Outcomes
All subjects were compliant with using the air purifier for
1 month as planned. Forty-six of the 49 submitted fully
completed survey questions at baseline and at 4 weeks
for analysis.
Of the 49 participating subjects, 46 subjects completed the trial, defined as having recorded the data on all
outcomes at 4 weeks postintervention. Eighty-nine percent of asthma sufferers had data on all outcomes at 4
weeks (n ¼ 16). For week 1 assessments, data were available on all 49 subjects.
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Table 1. Participants Characteristics.
Variables
Gender
Female
Male
Age
Mean (range)
Race
Asian or Pacific Islander
Black of African American
Hispanic or Latino
White/Caucasian
Middle Eastern
Active allergy symptoms
Yes
No
Asthma
Yes
No
Medication allergies and asthma
Yes
No

N (%)
27 (55.1)
22 (44.9)
40 (18–77)
6 (12.2)
1 (2.0)
5 (10.2)
36 (73.5)
1 (2.0)
38 (77.5)
11 (22.5)
18 (36.7)
31 (63.2)
37 (75.5)
12 (24.5)

Overall Symptom Score Results at Weeks 4 and 1
As indicated in Figure 1, there was a statistically significant change in overall TSS (TNSS þ TOSS) from baseline
to the 4-week time point (10.1 at baseline and 4.35 postintervention) resulting in a mean difference of 5.75 (95%
CI, 4.32–7.18; P < .0001). The resultant odds ratio was
19.5 (95% CI, 8.09–44.6) Indeed, all symptom elements
within TNSS and TOSS showed improvement (nasal congestion, itchiness, sneezing, runny nose, eye redness, secretion, and itchiness) (P < .001). Among subjects with active
respiratory allergies (n ¼ 36), there was a statistically significant change in overall symptom score from baseline to
the 4-week time point (11.5 at baseline and 4.53 postintervention) resulting in a mean difference of 6.97 (95%
CI, 5.56–8.38; P < .0001). The resultant odds ratio was
58.6 (95% CI, 19.3–162.5). As indicated in Figure 2,
there was a statistically significant change in overall symptom score from baseline to the 1-week time point (10.2 at
baseline and 5.7 postintervention) resulting in a mean difference of 4.5 (95% CI, 2.93–6.07; P < .0001). The resultant odds ratio was 7.8 (95% CI, 3.55–16.6). Again, all
symptom elements showed improvement (nasal congestion, itchiness, sneezing, runny nose, eye redness, secretion, and itchiness) (P < .001). Among subjects with active
allergies (n ¼ 38), there was a statistically significant
change in overall symptom score from baseline to the 1week time point (11.6 at baseline and 6.3 postintervention) resulting in a mean difference of 5.3 (95% CI,
3.64–6.96; P < .0001). The resultant odds ratio was
13.5 (95% CI, 5.3–32.7). Improvements seen at 1 week
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Pre-intervention

Outcomes

Mean

Post-intervention

SD Total Mean

Changes in outcomes post-intervention (all subjects)
Symptom score at 4 weeks from baseline 10.1 4.22
6.3 2.6
TNSS score at 4 weeks from baseline
TOSS score at 4 weeks from baseline
3.82 2.38
Sleep at 4 weeks from baseline
1.54 0.96

SD Total

46 4.35 2.6
46 3.04 1.9
46 1.3 1.3
46 0.43 0.58

Mean Difference
[95% CI] p-value

46
46
46
46

5.75 [4.32, 7.18] p<0.0001
3.26 [2.33, 4.19] p<0.0001
2.52 [1.74, 3.30] p<0.0001
1.11 [0.79, 1.43] p<0.0001

36
36
36
36

6.97 [5.56, 8.38] p<0.0001
3.80 [2.84, 4.76] p<0.0001
3.18 [2.40, 3.96] p<0.0001
1.30 [0.95, 1.65] p<0.0001

Mean Difference
95% CI

Changes in outcomes post-intervention (allergy subjects)
Symptom score at 4 weeks from baseline
TNSS score at 4 weeks from baseline
TOSS score at 4 weeks from baseline
Sleep at 4 weeks from baseline

11.5 3.5
6.9 2.45
4.6
2
1.75 0.91

36 4.53 2.5
36 3.1 1.62
36 1.42 1.33
36 0.45 0.56

-10
-5
0
5
10
Favors no intervention Favors intervention

Figure 1. Forest plot showing changes in outcomes at 4 weeks from baseline postintervention. Statistical improvements were seen in
total symptoms scores (TNSS þ TOSS), total nasal symptom scores (TNSS), total ocular symptom scores (TOSS), and sleep scores.
Greater improvements were seen in subjects with active respiratory allergies.

Pre-intervention

Post-intervention

Outcomes
Mean SD Total Mean
Changes in outcome post-intervention (all subjects)
Symptom score at 1 week from baseline
TNSS score at 1 week from baseline
TOSS score at 1 week from baseline
Sleep at 1 week from baseline

10.2 4.21
6.3 2.58
3.8 2.4
1.6 0.95

SD Total

49 5.7 3.7
49 3.7 2.4
49 1.9 1.8
49 0.77 0.77

Mean Difference
[95% CI] p-value

49
49
49
49

4.50 [2.93, 6.07] p<0.0001
2.60 [1.61, 3.59] p<0.0001
1.90 [1.06, 2.74] p<0.0001
0.83 [0.49, 1.17] p<0.0001

38
38
38
38

5.30 [3.64, 6.96] p<0.0001
3.10 [2.02, 4.18] p<0.0001
2.40 [1.55, 3.25] p<0.0001
0.78 [0.40, 1.16] p<0.0001

Mean Difference
95% CI

Changes in outcome post-intervention (allergy subjects)
Symptom score at 1 week from baseline
TNSS score at 1 week from baseline
TOSS score at 1 week from baseline
Sleep at 1 week from baseline

11.6 3.5
7 2.4
4.7 1.9
1.7 0.89

38 6.3 3.86
38 3.9 2.4
38 2.3 1.9
38 0.92 0.78

-10
-5
0
5
10
Favors no intervention Favors intervention

Figure 2. Forest plot showing changes in outcomes at 1 week from baseline postintervention. Statistical improvements were seen in total
symptoms scores (TNSS þ TOSS), total nasal symptom scores (TNSS), total ocular symptom scores (TOSS), and sleep scores. Greater
improvements were seen in subjects with active respiratory allergies.

continued for the entire 4-week testing period. Fortythree subjects had improved and 3 subjects had
worse TSS (baseline to exit, 1–8, 4–5, and 3–8). These
changes were not statistically significant. Subjects with
allergies and allergies/asthma both had reductions in
TSS that were statistically significant (P < .005). At 4
weeks, in the allergy group, there was a mean change in
score of 6.1 (initial score 10.4) and in the allergy/asthma
group, there was a mean change in score of 5.2 (initial
score 9.9).

TNSS Results at Weeks 4 and 1
There was a statistically significant change in TNSS from
baseline to the 4-week time point (6.3 at baseline and
3.04 postintervention) resulting in a mean difference of
3.26 (95% CI, 2.33–3.19; P < .0001; see Figure 1). The
resultant odds ratio was 13.3 (95% CI, 5.7–29.9).
Among subjects with active allergies (n ¼ 36), there was
a statistically significant change in TNSS from baseline

to 4 weeks (6.9 at baseline and 3.1 postintervention)
resulting in a mean difference of 3.8 (95% CI, 2.84–
4.76; P < .0001). The resultant odds ratio was 27.4
(95% CI, 9.8–71.4). There was also a statistically significant change in TNSS from baseline to the 1-week time
point (6.3 at baseline and 3.7 postintervention) resulting
in a mean difference of 2.6 (95% CI, 1.61–3.59;
P < .0001; see Figure 2). The resultant odds ratio was
6.61 (95% CI, 3.03–13.97). Among subjects with active
allergies (n ¼ 38), there was a statistically significant
change in TNSS from baseline to the 1-week time
point (7 at baseline and 3.9 postintervention) resulting
in a mean difference of 3.1 (95% CI, 2.02–4.18;
P < .0001). The resultant odds ratio was 10.35 (95%
CI, 4.14–24.71).

TOSS Results at Weeks 4 and 1
There was a statistically significant change in TOSS from
baseline to the 4-week time point (3.82 at baseline and
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1.3 postintervention) resulting in a mean difference of
2.52 (95% CI, 1.74–3.3; P < .0001; see Figure 1). The
resultant odds ratio was 10.8 (95% CI, 4.7–23.9).
Among subjects with active allergies (n ¼ 36), there was
a statistically significant change in TOSS from baseline
to the 4-week time point (4.6 at baseline and 1.42 postintervention) resulting in a mean difference of 3.18 (95%
CI, 2.4–3.96; P < .0001). The resultant odds ratio was
29.6 (95% CI, 10.5–77.6). There was also a statistically
significant change in TOSS from baseline to the 1-week
time point (3.80 at baseline and 1.90 postintervention)
resulting in a mean difference of 1.90 (95% CI,
1.06–2.74; P < .0001; see Figure 2). The resultant odds
ratio was 5.05 (95% CI, 2.35–10.59). Among subjects
with active allergies (n ¼ 38), there was a statistically significant change in TOSS from baseline to 1 week (4.7 at
baseline and 2.3 postintervention) resulting in a mean
difference of 2.4 (95% CI, 1.55–3.25; P < .0001). The
resultant odds ratio was 9.83 (95% CI, 3.94–2.4).

Sleep Quality at Weeks 4 and 1
There was a statistically significant change in sleep quality from baseline to the 4-week time point (1.54 at baseline and 0.43 postintervention) resulting in a mean
difference of 1.11 (95% CI, 0.79–1.43; P < .0001; see
Figure 1). The resultant odds ratio was 12.1 (95% CI,
5.2–27.9). Among subjects with active allergies (n ¼ 36),
there was a statistically significant change in sleep quality from baseline to the 4-week time point (1.75 at baseline and 0.45 postintervention) resulting in a mean
difference of 1.3 (95% CI, 0.95–1.65; P < .0001). The
resultant odds ratio was 22.5 (95% CI, 8.2–57.8).
There was a statistically significant change in sleep quality from baseline to the 1-week time point (1.6 at baseline and 0.77 postintervention) resulting in a mean
difference of 0.83 (95% CI, 0.49–1.17; P < .0001; see
Figure 2). The resultant odds ratio was 5.7 (95% CI,
2.63–11.9). Among subjects with active allergies
(n ¼ 38), there was a statistically significant change in
sleep quality from baseline to the 1-week time point
(1.7 at baseline and 0.92 postintervention) resulting in
a mean difference of 0.78 (95% CI, 0.4–1.16; P < .0001).
The resultant odds ratio was 5.40 (95% CI, 2.26–12.05).

Asthma Control (n ¼ 16) at 4 Weeks
There was a statistically significant change in asthma
symptoms from baseline to those seen at 4 weeks (2.06
at baseline and 0.75 postintervention) resulting in a
mean difference of 1.31(95% CI, 0.45–2.18; P ¼ .006).
Medication Use and Adverse Events. Allergy and asthma
medication use at baseline was reported in Table 1. At
4 weeks, 34 of the 37 participants who were taking
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medications provided medication use details; 67.7%
(n ¼ 23) reported a decrease in medication use and
32.3% (n ¼ 11) reported no decrease in medication use
(P ¼ .006). Adverse events related to the air purifier were
not reported. Two subjects complained of headaches,
1 due to a sinus infection and 1 who had preexisting
headaches at baseline. Six complained of light and
14 complained of noise.

Discussion
In our study, we evaluated the clinical efficacy of using a
portable home air purifier with a novel air filtration technology, PECO. Our results demonstrate a significant
improvement in nasal-related allergy symptoms and
ocular-related allergy symptoms in those who used it
daily. The significant improvements were seen after
1 week of use of the air purifier. Moreover, the symptom
reductions that were seen were sustained with continuous use at 4 weeks after initiation. All symptom elements
showed significant improvement during weeks 1 to
4 (nasal congestion, itchiness, sneezing, runny nose, eye
redness, secretion, and itchiness). In addition, we noted
significant improvements in sleep quality after use of the
air purifier at weeks 1 to 4. Total symptom reduction
and improvements in sleep were even more profound
in those with at least moderate, active allergy symptoms
at baseline. A small subset of individuals who tried the
air purifier also had a history of asthma. For those who
reported asthma symptoms, there was a significant
improvement in their symptoms after 4 weeks of use.
PECO is an air purification technology that destroys
pollutants 1000 times smaller than HEPA filters can
trap.5,6 The technology works by emitting ultraviolet-A
light on to a filter membrane coated with nanoparticles.
This creates a photoelectrochemical reaction on the surface of the filter that will break down the molecular structure of organic particles in the air. Although a traditional
filter can only collect pollutants on the filter surface such
that they can potentially reenter the air stream, PECO
destroys pollutants as small as 0.1 nm. HEPA filters by
contrast can only capture pollutants efficiently down to
300 nm in size.16 We felt that given the exponential
improvement in PECO technology’s filtering ability that
there could be clinical benefits in symptoms related to
allergy, VOCs, and particulate matter exposure in the
home, and this would amount to a preventative strategy
that could not only improve outcomes but decrease overthe-counter and prescription medication usage, since
these triggers are effectively reduced. Prior to the current
study, we have shown in detail the capacity of this filtration technology but have not pursued studies of clinical
efficacy (see Figures 3 and 4).5,7
Despite improvements in therapy and drug delivery
for patients with respiratory allergies and asthma, there
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Figure 3. Aspergillus niger spores (A) In dark (B) being oxidized with PECO as noted on electron microscopy.9

Figure 4. Bacillus subtilis endospores (A) In dark (B) being oxidized with PECO as noted on electron microscopy.9

is a significant need for improvement in the overall treatment strategy that may also include preventive methods
such as air filtration. For example, up to 50% of asthmatics are not under optimal control.17,18 Seasonal or
perennial allergic symptoms are present in 10% to
40% of the U.S. population, resulting in at least 6 billion
dollars in overall health-care expenditures per year 1,19.
In addition, compliance with medication use can be
problematic and for some classes of drugs, there may
be long-term adverse events.20 For these reasons, various
environmental interventions have been evaluated to further address these problems.
One of the landmark studies for asthma patients using
multiple environmental interventions was the inner-city

asthma study group randomized trial.21 This study
included the use of HEPA air filtration in the child’s
bedroom if exposed to secondhand smoke or sensitized
to cat, dog, or mold allergens. It appeared that comprehensive intervention which included air filtration as well
as allergen covers, vacuum cleaning, and pest control
helped reduce asthma-related exacerbations and symptoms, but the specific improvements that may have been
attributable to air purification alone were not evaluated.
Several additional studies have evaluated the role of
air filtration alone in improving respiratory allergy
symptoms and asthma. A meta-analysis analyzing the
10 trials that were performed between 1973 through
1999 including asthma patients reported significantly
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lower TSS and lower sleep disturbance score; however,
heterogeneity of results weakened the inferences from
these trials.22 Some trials have specifically looked at
the clinical benefit of using portable room air purifiers
as compared to whole home filtration. In this context,
while air purification with HEPA filtration has provided
a variable degree of benefit for some individuals, ionic
electrostatic room air cleaners appear to be of no benefit
and may produce ozone, a potentially harmful respiratory irritant.4 In a randomized trial using portable
HEPA air cleaners and HEPA vacuum cleaning in the
bedroom and living room in 30 asthmatics living with an
indoor cat or dog, there were statistical improvements in
asthma outcomes including bronchial reactivity and
treatment requirements.23 In another study by Gore
et al., HEPA portable units reduced the amount of cat
allergen in the room. However, this effect was mitigated
when the cat was removed from the room.24 Batterman
et al. reported a 2-month long study evaluating the
effects of HEPA portable units in the homes of cigarette
smokers. Results showed a reduction in particulate
matter concentrations; however, clinical effects were
not studied.25 Sulser et al. evaluated children sensitized
to cat or dog allergens who used portable air purification
with HEPA technology in the living room and bedroom
in a randomized controlled trial.26 Although HEPA air
cleaners retained airborne pet allergens, no effect on disease activity or allergen concentrations in bulk dust samples was observed. Randomized studies have more
recently looked at the use of HEPA filtration in the
breathing zone utilized during sleep. Pedroletti et al.
evaluated the use of HEPA filtration in the sleep breathing zone for teenagers and young adults concluding that
clean air, administered directly to the breathing zone
during sleep, can have a positive effect on bronchial
inflammation and quality of life.27 Stillerman et al. utilized a combination of HEPA filtration along with a dust
mite proof pillowcase. Significant improvements were
seen in nocturnal nasal and ocular allergy symptoms
and quality of life for the active versus placebo device.16
While there generally appears to be some improvement in disease management for both allergy and
asthma sufferers using HEPA filtration, there remain
several notable drawbacks to this technology. Even
with maximum filtering efficiency, particulate matter
cannot be completely filtered from the air by HEPA.28
In addition, it is unclear to what extent HEPA filtration
can decrease mold spore counts, if at all, and may allow
for these spores to recirculate in the air exacerbating
allergy and asthma.29,30 A major drawback of HEPA
filtration is that it is not able to remove the smaller
allergens bacteria, viruses, and VOCs that are smaller
than 300 nm.16 This group can be the source of allergies,
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infection, and respiratory irritation leading to allergy or
asthma exacerbation, which have yet to be included in
filtration methods to date for the prevention or improvement of these symptoms. In contrast, PECO technology
allows for both physical filtration, like with HEPA, and
photocatalysis to oxidize organic material into its trace
elements, notably water and carbon dioxide. Unlike
HEPA filtration, PECO technology has been shown to
completely oxidize and destroy pollutants such as mold,
bacteria, viruses, and VOCs and thus represents substantial improvement in air filtration over any technology
available in the home.5,7
Our current study has several strengths and limitations. The main limitation is the lack of a comparator
and being a pre–post study, the findings are subject to
regression to the mean. To conclusively address the efficacy of the air purifier, an adequately powered, designed,
and executed randomized controlled trial is needed.
Although we did not have a “placebo” arm, each
person does serve as their own control, which is not
unlike other studies in the field.31 We were unable to
differentiate allergic versus nonallergic rhinitis or
asthma subjects due to the limitations of our current
study design. We also knew upfront that we would be
unable to measure levels of allergens and fully assess or
control other environmental interventions used by the
subjects given their heterogeneity. This issue can be conclusively addressed only in a randomized controlled trial
where groups would be balanced for the environmental
factors. We utilized self-reporting of symptoms, which is
not unusual for allergy studies. However, for asthma,
there are objective measurements that can now be performed at home such as forced expiratory volume and
peak expiratory airflow. Future studies could incorporate such measurements, especially with a larger group
of asthmatics. In such a study, it may be prudent to
phenotype patients prior to study so as to understand
which of the various asthmatic subgroups reap the greatest benefit. Such a study is beyond the scope of the current work. Nevertheless, asthmatics in our study showed
fewer asthma-related symptoms, strongly indicative of a
positive effect. We contend that an even greater magnitude of symptom score reduction would have been seen
with subjects who have worse allergic symptoms, but this
awaits explicit testing.
In conclusion, we found significant and sustained
improvements in respiratory allergy symptoms within a
week of using portable air filtration using PECO technology. Improvements were also noted in sleep quality.
There was a benefit after 1-week use which was sustained
for the entire 4-week use of the air purifier. In the subset
of those suffering from asthma, there appeared to be an
improvement in asthma-related symptoms. In summary,
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PECO is a novel technology that could be very useful in
the future management of respiratory allergies
and asthma.
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